A guinea pig model of bovine pneumonic pasteurellosis.

The induction of pneumonic pasteurellosis in guinea pigs (Cavia porcellus) was examined. Specific pathogen free male guinea pigs were anesthetized and a tracheostomy performed to introduce 10(5), 10(4) or 10(3) Pasteurella haemolytica-A1 into the left principal bronchus. The surgical site was closed with tissue adhesive and staples and the animals were monitored for signs of respiratory tract infection. Within 24 hours after inoculation they became depressed, anorectic, pyretic and dyspneic. Fibrinous pleuropneumonia with prominent areas of necrosis and hemorrhage was present. Pericardial effusion was a frequent finding. There was infiltration of the pleura and alveoli with degenerate heterophils and macrophages, a hyperplastic mesothelium and fibrin exudation on the pleura and within alveoli. Hemorrhage, congestion, consolidation, edema and fibrin exudation were prominent in the hilar region of the lungs. Bacterial colonies were evident in all airways. More bacteria were recovered from infected lungs than were inoculated (p less than 0.05) indicating P. haemolytica was actively multiplying in the lungs. Hematological and clinical chemistry data were consistent with fibrinous pneumonia, however, blood cultures were positive for P. haemolytica in 61% (11/18) of animals sampled. Examination of pneumonic pasteurellosis in guinea pigs may be useful in studying pathogenetic and pathological features applicable to bovine pneumonic pasteurellosis (shipping fever pneumonia).     

The evolution of vaccines for bovine pneumonic pasteurellosis

Since the early 1900s bovine pneumonic pasteurellosis has been recognised as a major economic problem to European and North American cattle industries. Initial attempts to prevent the disease were complicated by incomplete knowledge of the causative organisms. Despite some early reports of vaccine-induced protection against disease, initial vaccines were of questionable protective value. From the late 1950s to the 1970s Pasteurella haemolytica and P multocida bacterins were the primary type of vaccine used commercially and experimentally. When viruses, most notably bovine herpesvirus 1 (infectious bovine rhinotracheitis virus) and parainfluenza-3 virus, were found to be associated with bovine respiratory disease, viral vaccines were used in attempts to prevent pneumonic pasteurellosis. Combinations of bacterins and viral vaccines were also developed and evaluated. Collectively, bacterins, viral vaccines and bacterin-virus combinations did not consistently reduce disease in experimental trials or field use. By the 1980s some studies using live vaccines were reportedly successful in reducing the incidence of pneumonic pasteurellosis. Current experimental studies revolve around the identification and incorporation of specific Pasteurella species antigen extracts into vaccines. The efficacy of these new extract vaccines is yet to be determined.     

Prevention of experimental bovine pneumonic pasteurellosis with an extract of Pasteurella haemolytica.

A total of 36 calves were used in three experiments to test the efficacy of a potassium thiocyanate extract of Pasteurella haemolytica in protecting against experimental pneumonia. In each of experiments A and B, 12 calves were divided into three equal groups. The first group was vaccinated with an aerosol of a potassium thiocyanate extract twice, two weeks apart; the second group was vaccinated subcutaneously once only with the same extract. The third group of calves in both experiments remained as unvaccinated controls. In experiment C, six calves were vaccinated intramuscularly and six were left as controls. Approximately one month after vaccination all calves were challenged with an aerosol of bovine herpesvirus 1 (isolate 108) followed in 4 d by an aerosol of P. haemolytica type A1 (the same strain from which the potassium thiocyanate extract had been made). Varying degrees of protection against subsequent development of experimental pneumonic pasteurellosis in cattle were seen in vaccinated calves as compared to control calves in these experiments. The results indicate that protection of cattle against pneumonic pasteurellosis may prove possible with a sub-cellular extract of P. haemolytica.     

Experimental bovine pneumonic pasteurellosis. I. Prevention of the disease.

Fifteen three- to six-month old Hereford-cross calves were divided into three groups. The first group was inoculated with bovid herpersvirus 1 (Strain 108), the second with a commercial intranasal vaccine against bovid herpesvirus 1 and the third group acted as controls. At least three weeks after vaccination, all calves were weaned, placed in an environmental chamber at 25.0 degrees C (days) and -13.3 degrees C (nights) and challenged with an aerosol of bovid herpesvirus 1 followed four days later by an aerosol of Pasteurella haemolytica. All surviving calves were sacrificed four days after the second aerosol. None of the calves inoculated with bovid herpesvirus 1 virus or the commercial vaccine developed a generalized pneumonia, although there were one or two nodules (4--8 mm diameter) in two of the calves given the commercial vaccine. Four of the five control calves had extensive lobar pneumonia at necropsy, two of the five died from the disease. Details of the clinical, pathological, bacteriological, virological and some of the serological findings are reported.     

A field evaluation of the efficacy of two vaccines against ovine pneumonic pasteurellosis

Two vaccines against pneumonic pasteurellosis were evaluated for efficacy in lambs transported by sea from New Zealand to Saudi Arabia. One vaccine contained whole cell antigens of Pasteurella haemolytica A2 grown under iron restricted conditions. The other contained Pasteurella haemolytica A1 cell surface and leucotoxin antigens. There was no clear evidence of either vaccine leading to a lower pneumonia death or lesion rate than for the control group.     

Clinical and pathological evaluation of sulbactam/ampicillin for treatment of experimental bovine pneumonic pasteurellosis

An experiment was conducted to evaluate the efficacy of sulbactam/ampicillin for treatment of bovine pneumonic pasteurellosis. Twenty-one Hereford calves were experimentally infected with bovine herpesvirus-1 and an ampicillin-resistant strain of Pasteurella haemolytica, then treated for three days with either sulbactam/ampicillin, chloramphenicol, or a placebo. The treatments were evaluated by comparing clinical illness scores, total sick days, weight changes, mortality rates, and postmortem lung scores between treatment groups. Both antibiotics were highly effective in reducing respiratory disease in the experimentally infected calves. The clinical response to sulbactam/ampicillin treatment was comparable with that of chloramphenicol and was significantly improved compared with the response to the placebo treatment. These findings suggest that the efficacy of sulbactam/ampicillin may be comparable to that of chloramphenicol for treatment of pneumonic pasteurellosis involving ampicillin-resistant strains of P. haemolytica.     

Efficacy of a live Pasteurella multocida vaccine for the prevention of experimentally induced bovine pneumonic pasteurellosis

Seventeen Holstein-Friesian calves weighing an average of 139.8 +/- 13.5 (mean +/- standard deviation) kg were used in a study to determine the efficacy of a live vaccine containing of Pasteurella multocida A:3 and Pasteurella haemolytica A:1. Eleven calves received the vaccine by intramuscular injection in the right shoulder, whereas six calves received vaccine diluent and served as non-vaccinated controls. Fourteen days following vaccination (Day 15) all calves were inoculated deep intranasally with 3.6 X 10(7) TCID50 bovine herpes virus-1. On Day 16, calves were stressed by transports, and on Day 17 calves were challenged intratracheally with P. multocida A:3. On Day 22 calves were euthanized and necropsied, and tissues were collected for pathological and microbiological evaluations. Scores were assigned to each calf based on the severity of observed clinical signs. Macroscopic lung lesions were expressed as percentage of tissue involved relative to the total lung tissue of a calf. Plasma fibrinogen concentration, rectal temperature, serum antibody level, microscopic appearance of lung, and microbiologic results were also recorded for analyses. The control calves had significantly higher clinical-sign scores (P less than 0.05) and more severe gross lesions (P less than 0.05) than the vaccinated calves. Although the vaccinated calves had a slight increase of immunoglobulins M and G classes, the differences were not statistically significant (P greater than 0.05, P greater than 0.05). The results of the study indicate that the live Pasteurella vaccine is effective against experimental P. multocida infection in calves.     

Preliminary studies with a live streptomycin-dependent Pasteurella multocida and Pasteurella haemolytica vaccine for the prevention of bovine pneumonic pasteurellosis.

Twelve Pasteurella-free Holstein-Friesian calves were used in a study to test the efficacy of a live streptomycin-dependent Pasteurella multocida A:3 and streptomycin-dependent Pasteurella haemolytica A1 vaccine. The calves were inoculated intramuscularly twice at 14-day intervals with either the streptomycin-dependent vaccine, containing 1 X 10(6) colony forming units/mL P. multocida and 4 X 10(8) colony forming units/mL P. haemolytica, commercial bacterin, or phosphate buffered saline. Two weeks following the second vaccination, all calves were challenged by intranasal inoculation of 10(8) TCID50/4.0 mL infectious bovine rhinotracheitis virus followed three days later by intratracheal injection with 2.3 X 10(7) colony forming units/mL of a 16 hour culture of P. multocida A:3 and 2.6 X 10(8) colony forming units/mL of an 8 hour culture of P. haemolytica A1. Seven days after challenge with Pasteurella, calves were killed for collection of tissues at necropsy. Each calf was given a score based on macroscopic and microscopic lesions. The scores for the calves receiving live vaccines were significantly lower (p less than 0.025) than those for the controls. Also, the calves receiving live vaccines had a significant (p less than 0.05) increase in the level of serum antibody to P. haemolytica. The results of this preliminary study showed that the streptomycin-dependent vaccine offered better protection than the commercial bacterin against a virulent homologous challenge.     

Characterization of a Pasteurella multocida (serotype B) bovine pneumonic pasteurellosis model and the effect of antimicrobials during peracute infection

A method to produce bovine pneumonic pasteurellosis for experimental purposes was studied and the clinical response of experimentally infected calves to selected antimicrobials was characterized. Male Holstein calves stressed with multiple hot and cold water applications followed by intratracheal inoculation of broth cultures of Pasteurella multocida serotype B developed acute clinical illness consistent with pneumonia. Infected, untreated calves consistently developed classic pneumonic pasteurellosis, infected calves treated with either oxytetracycline or sulfadimethoxine recovered from acute clinical disease, and the uninfected controls remained healthy. This disease model offers potential for use in pharmacokinetic and target tissue drug concentration studies and for dosage titration of drugs intended for treatment of bacterial pneumonias.     

Experimental model of swine pneumonic pasteurellosis using crude Actinobacillus pleuropneumoniae cytotoxin and Pasteurella multocida given endobronchially.

This study was designed to develop and characterize a swine pneumonic pasteurellosis model by concurrent introduction of Pasteurella multocida type A and Actinobacillus pleuropneumoniae crude cytotoxin. After a series of preliminary experiments, a combination of 4 x 10(9) P. multocida and 4,000 toxic units of A. pleuropneumoniae crude cytotoxin was determined to produce optimal results. A total of 48 pigs were divided into four groups of 12 pigs each. The control group received buffered saline only. Four pigs from each group were randomly selected for necropsy 3, 7 and 14 days postinoculation (PI). Inoculation of pigs with P. multocida and A. pleuropneumoniae cytotoxin (group 1) resulted in moderate to severe pneumonia. Pasteurella multocida was isolated from pneumonic lesions, grossly normal lung, and bronchial lymph nodes of all group 1 pigs throughout the 14 day experimental period. Pathological changes typical of field cases of swine pneumonic pasteurellosis were produced. Pigs inoculated with P. multocida alone (group 2) had pneumonic lesions and P. multocida was reisolated from lungs at three days PI. Pasteurella multocida was not isolated from these pigs at 7 and 14 days PI, except for one pig in which an abscess developed in the thorax. Pulmonary lesions induced by A. pleuropneumoniae crude cytotoxin alone (group 3) were transient and resolved by seven days PI. Group 1 pigs had significantly greater lung lesion volumes than group 2 and 3 pigs at 3, 7 and 14 days PI. Statistical analysis indicated a significant interactive effect of P. multocida and A. pleuropneumoniae cytotoxin on the development of lung lesion volumes at 7 and 14 days PI (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)     

Effectiveness of various therapeutic regimens for bovine brucellosis

Various chemotherapeutic regimens were evaluated in 48 culture-positive dairy cows. Cessation of shedding of Brucella abortus from udder secretions and absence in selected tissues at necropsy were criteria of success. A combination of a long-acting oxytetracycline and streptomycin eliminated Brucella in 10 of 14 (71.4%) cows. Two cows that were retreated with the same regimen also became culture-negative. Other treatment regimens, including the use of liposome-encapsulated antibiotics, were less successful. Serotests were a poor criterion of effectiveness.     

Bovine pneumonic pasteurellosis: evaluation of interactions between bovine pulmonary lavage cells and Pasteurella haemolytica (biotype A, serotype 1), using a luminol-dependent chemiluminescence assay

In vitro interactions of bovine pulmonary lavage cells (PLC) and pathogenic isolates of Pasteurella haemolytica biotype A, serotype 1, were examined, using a luminol-dependent chemiluminescence (LDCL) assay. The PLC containing high concentrations of bovine alveolar macrophages were incubated with living and heat-killed P haemolytica at bacteria to PLC ratio of approximately 1:1. Kinetics of the mean LDCL response of bovine PLC to heat-killed P haemolytica cells were characterized by a gradual increase in the amount of light emitted over 150 minutes followed by a slight decrease at 180 minutes. In contrast, the LDCL responses of reaction mixtures containing living P haemolytica were characterized by the development of a maximal response at 60 minutes followed by a continued precipitous decrease in light emission to background values by 150 minutes. Differences were not noticed in the LDCL response of PLC suspensions from the same cow to 3 P haemolytica isolates. In each instance, reaction mixtures containing heat-killed bacteria had a similar LDCL profile that was characterized by continuous production of light over 180 minutes, whereas all reaction mixtures containing living bacteria underwent a precipitous decrease in light emission, which eventually resulted in a complete cessation of chemiluminescence. The PLC suspensions from different cattle did not respond to bacterial stimuli uniformly, with respect to the amplitude or detailed nature of the LDCL profile. The time that lapsed between the addition of living P haemolytica to PLC suspensions and the complete cessation of chemiluminescence varied for different cows.(ABSTRACT TRUNCATED AT 250 WORDS)     

A simple procedure to secure an indwelling jugular vein catheter to the neck of cattle for repeated blood sampling.

A procedure to secure a jugular vein catheter system to the neck of cattle is described. A wide-mouthed polypropylene bottle attached to a halter strap provided a secure container for the catheter. This device allowed convenient access to the catheter for repeated sampling and, apparently, reduced discomfort to the cattle.     

Use of topical bovine thrombin in an anti-coagulated rat model of hepatic injury

The need for surgical hemostasis in patients treated with anticoagulant medications is a concern. This study assessed a bovine-derived topical hemostat (FastAct, FA) using a partial hepatectomy hemorrhage model in anticoagulated rats. Ninety rats were randomly assigned to receive preoperative heparin, warfarin, or nothing (n = 30/treatment). Within each treatment group, FA, saline, direct pressure (DP), electrocautery, or nothing (n = 6/group) was applied to the hepatectomy site. Eight additional rats were used for assessment of the preoperative anticoagulant regimen. Rats that were not anticoagulated and received FA had faster clot times and less hemorrhage than those receiving DP (P < 0.05). In warfarin-pretreated rats, FA resulted in faster coagulation times than saline or DP and less hemorrhage than saline (P < 0.05). No differences were detected in heparinized rats. Across all groups, rats receiving FA lost less blood and formed clots more frequently than saline (P < 0.05). FA may be useful to treat hemorrhage from hepatic lacerations in anticoagulated patients.     

Use of topical bovine thrombin in an anti-coagulated rat model of hepatic injury

The need for surgical hemostasis in patients treated with anticoagulant medications is a concern. This study assessed a bovine-derived topical hemostat (FastAct, FA) using a partial hepatectomy hemorrhage model in anticoagulated rats. Ninety rats were randomly assigned to receive preoperative heparin, warfarin, or nothing (n=30/treatment). Within each treatment group, FA, saline, direct pressure (DP), electrocautery, or nothing (n=6/group) was applied to the hepatectomy site. Eight additional rats were used for assessment of the preoperative anticoagulant regimen. Rats that were not anticoagulated and received FA had faster clot times and less hemorrhage than those receiving DP (P<0.05). In warfarin-pretreated rats, FA resulted in faster coagulation times than saline or DP and less hemorrhage than saline (P<0.05). No differences were detected in heparinized rats. Across all groups, rats receiving FA lost less blood and formed clots more frequently than saline (P<0.05). FA may be useful to treat hemorrhage from hepatic lacerations in anticoagulated patients.